The SnapPath™ platform is a live tumor cell-processing device with first-in-class, functional, ex vivo biomarker tests to improve drug development and inform clinical decision making for targeted cancer therapeutics. The automated platform stimulates a patient’s live tumor cells to evoke a Functional Signaling Profile (FSP) of the signal transduction network that is not possible using static, genomic biomarkers from dead, fixed tissue. These predictive FSPs generated by the SnapPath™ platform will enable a new level of personalized medicine for cancer patients with any solid tumor, including melanoma, breast, lung, colorectal, and pancreatic, so that the right drug can be given to the right patient at the right time. The intended users are radiologists, pathologists, laboratory and pathology technologists and researchers.